NUGENEREX IMMUNO-ONCOLOGY, INC.
company.status.inactiveCIK 1804585fmd_1739YSZ6KVBGJ8B1BDNPV8AYHYManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Aug 01, 2018 to Apr 30, 2021, 11 periods
Latest annual · FY2020
Millions- Operating income
- (1)
- Net income
- (2)
Latest quarter · Q2 FY2021
Millions- Operating income
- (2)
- Net income
- (2)
NUGENEREX IMMUNO-ONCOLOGY, INC. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2020 | FY2019 | Change | Source |
|---|---|---|---|---|
| Operating income | -$733,614 | -$392,741 | 10-K 2020-10-29 · proof | |
| Net income | -$1.5 million | -$1.1 million | 10-K 2020-10-29 · proof | |
| Total assets | $84 | $389 | -78.4% | 10-K 2020-10-29 · proof |
| Total liabilities | $5.8 million | $4.4 million | +33.2% | 10-K 2020-10-29 · proof |
| Cash and cash equivalents | $84 | $389 | -78.4% | 10-K 2020-10-29 · proof |
- What was NUGENEREX IMMUNO-ONCOLOGY, INC.'s operating income in fiscal 2020?
- NUGENEREX IMMUNO-ONCOLOGY, INC. reported operating income of -$733,614 for fiscal 2020 (the year ended Jul 31, 2020), against -$392,741 the year before. Source: the 10-K filed with the SEC on Oct 29, 2020. SEC
- What was NUGENEREX IMMUNO-ONCOLOGY, INC.'s net income in fiscal 2020?
- NUGENEREX IMMUNO-ONCOLOGY, INC. reported net income of -$1.5 million for fiscal 2020 (the year ended Jul 31, 2020), against -$1.1 million the year before. Source: the 10-K filed with the SEC on Oct 29, 2020. SEC
- What are NUGENEREX IMMUNO-ONCOLOGY, INC.'s total assets?
- As of Jul 31, 2020, NUGENEREX IMMUNO-ONCOLOGY, INC. reported total assets of $84, against $389 a year earlier (-78.4%). Source: the 10-K filed with the SEC on Oct 29, 2020. SEC
- What are NUGENEREX IMMUNO-ONCOLOGY, INC.'s total liabilities?
- As of Jul 31, 2020, NUGENEREX IMMUNO-ONCOLOGY, INC. reported total liabilities of $5.8 million, against $4.4 million a year earlier (+33.2%). Source: the 10-K filed with the SEC on Oct 29, 2020. SEC
- What are NUGENEREX IMMUNO-ONCOLOGY, INC.'s cash and cash equivalents?
- As of Jul 31, 2020, NUGENEREX IMMUNO-ONCOLOGY, INC. reported cash and cash equivalents of $84, against $389 a year earlier (-78.4%). Source: the 10-K filed with the SEC on Oct 29, 2020. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1804585&period_type=annual&limit=5"Information only, not investment advice.